Welcome to our dedicated page for LENZ Therapeutics SEC filings (Ticker: LENZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LENZ Therapeutics, Inc. filings document the company’s transition from ophthalmic product development to commercialization of VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults. Form 8-K disclosures cover financial results, FDA approval and U.S. availability of VIZZ, product launch updates, safety-related communications, and capital-raising activity under an at-the-market sales agreement.
The company’s proxy and governance materials address shareholder voting matters, executive and board governance, material agreements, capital-structure disclosure, and operating and financial results. The filing record also captures regulatory and commercial disclosures tied to VIZZ, including product approval, launch-stage operations, financing transactions, and risk-related information relevant to a pharmaceutical company commercializing an ophthalmic prescription product.
LENZ Therapeutics, Inc. reports changes to its Board of Directors. On June 30, 2026, director Zach Scheiner resigned from the Board and all its committees, effective immediately.
The company states his resignation did not arise from any dispute or disagreement over its operations, policies or practices. On the same date, the Board reduced its size to six members and appointed Jeff George to the Audit Committee, which now consists of Shelley Thunen, Frederic Guerard and Jeff George.
LENZ Therapeutics, Inc. Schedule 13G discloses that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 1,603,512 shares of Common Stock, representing 5.1% of the class as shown on the cover page dated 06/23/2026.
The filing states these shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers; a joint filing agreement dated June 25, 2026 is attached.
LENZ Therapeutics reported an option grant tied to RA Capital–affiliated entities. A stock option for 22,100 shares of common stock was awarded with an exercise price of $6.63 per share and an expiration date of June 15, 2036.
All 22,100 option shares vest on the earlier of June 15, 2027 or the next annual stockholder meeting, subject to Dr. Scheiner continuing as an Outside Director under the company’s policy. Under Dr. Scheiner’s arrangement with RA Capital, any net cash or stock from exercising this option is turned over to RA Capital for the benefit of its funds and account, and the reporting persons disclaim beneficial ownership beyond any pecuniary interest.
LENZ Therapeutics director George Jeffrey P. received a stock option grant covering 22,100 shares of common stock. The option has an exercise price of $6.63 per share and expires on June 15, 2036.
All 22,100 shares vest in a single tranche, provided he continues to serve as an Outside Director, on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders. Following this grant, he holds options for 22,100 shares directly.
LENZ Therapeutics director Kimberlee C. Drapkin received a stock option grant for 22,100 shares of common stock at an exercise price of $6.63 per share. The option expires on June 15, 2036 and represents a compensation-related award, not an open-market purchase or sale.
All 22,100 option shares vest in a single installment, provided she continues to serve as an Outside Director. Vesting occurs on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders. Following this grant, she holds 22,100 options directly.
LENZ Therapeutics director James W. McCollum received a new stock option grant for 22,100 shares of common stock. The option has an exercise price of $6.63 per share and expires on June 15, 2036. Following this grant, he holds options for 22,100 shares directly.
According to the terms, all 22,100 option shares vest in a single tranche if he continues serving as an Outside Director through the vesting date. Vesting occurs on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders.
LENZ Therapeutics, Inc. reported that director Shelley B. Thunen received a grant of stock options for 22,100 shares of common stock at an exercise price of $6.63 per share. These options expire on June 15, 2036 and will vest 100% on June 15, 2027 or the next annual stockholder meeting, provided she continues as an Outside Director.
LENZ Therapeutics director Frederic Guerard received a grant of stock options for 22,100 shares of common stock. The options have an exercise price of $6.63 per share and expire on June 15, 2036. Following this grant, Guerard holds 22,100 derivative securities directly.
According to the vesting terms, all 22,100 options vest 100% on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders, as long as he continues to serve as an Outside Director under the company’s Outside Director Compensation Policy.
LENZ Therapeutics director-related entities received a new stock option award linked to board service. A stock option covering 22,100 shares of common stock was granted with an exercise price of $6.63 per share and an expiration date of June 15, 2036. The option vests 100% on the earlier of June 15, 2027 or the next annual stockholder meeting, provided the reporting person continues as an Outside Director. Under an arrangement with RA Capital Management, L.P., the option is held for the benefit of the RA Capital Healthcare Fund, the RA Capital Nexus Fund II, and a separately managed account, and the reporting person disclaims beneficial ownership because any net proceeds must be turned over to the adviser to offset advisory fees.
LENZ Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held on June 12, 2026. Of the 31,354,394 common shares outstanding as of April 14, 2026, 24,442,068 shares were represented in person or by proxy.
Stockholders elected Class II directors Evert Schimmelpennink, Jeff George, and Shelley Thunen to serve until the 2029 annual meeting, with each receiving more votes for than withheld. Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.